In a mouse model of colorectal cancer (CT26) targeting VEGFR therapy, it was found that targeting VEGF-a-VEGFR can reduce the co-expression of inhibitory receptors (PD-1, Tim-3, CTLA-4, and Lag-3) related to T cell failure and restore the CD8+ T cells infiltration into the tumor to produce IFN- γ ability (114). Here, HAVCR2 is linked to neoplasm.